Article citationsMore>>

Shaw, A.T., Gandhi, L., Gadgeel, S., Riely, G.J., Cetnar, J., West, H., et al. (2016) Alectinib in Alk-Positive, Crizotinib-Resistant, Non-Small-Cell Lung Cancer: A Single-Group, Multicentre, Phase 2 Trial. The Lancet Oncology, 17, 234-242.
https://doi.org/10.1016/s1470-2045(15)00488-x

has been cited by the following article:

• TITLE: Ceritinib-Induced Organising Pneumonitis

  AUTHORS: Boon Hau Ng, Hsueh Jing Low, Nik Nuratiqah Nik Abeed, Nor Safiqah Sharil, Rose Azzlinda Osman, Mohd Imree Azmi, Marfuah Eezamuddeen, Andrea Yu-Lin Ban

  KEYWORDS: Ceritinib, Pneumonitis, Acute Respiratory Distress Syndrome, Corticosteroids

  JOURNAL NAME: Open Access Library Journal, Vol.11 No.9, September 5, 2024

  ABSTRACT: Even though tyrosine kinase inhibitors (TKI) improve survival in non-small cell lung cancer (NSCLC), it is related to the risk of drug-induced pneumonitis. Whilst little is known regarding TKI-induced pneumonitis, adverse reactions carry a significant mortality rate and impact the available treatment options. Here, we present a case of an elderly gentleman diagnosed with metastatic ALK-positive NSCLC, who initially experienced ceritinib-induced skin vasculitis and subsequently developed acute respiratory distress syndrome upon being re-challenged with ceritinib. The patient’s clinical and radiological condition showed improvement after initiating intravenous methylprednisolone and discontinuing the targeted therapy. Ceritinib-associated pneumonitis represents a rare form of pulmonary toxicity, emphasising the importance of early identification and intervention to mitigate mortality risk.